Biogen price target raised to $200 from $190 at Wells Fargo

Wells Fargo raised the firm’s price target on Biogen (BIIB) to $200 from $190 and keeps an Equal Weight rating on the shares post the Q4 report. The firm expects the company’s 2026 launch execution to remain steady. Biogen’s near-term late-stage catalysts can improve outlook toward the end of the decade, the analyst tells investors in a research note.